Indicia Biotechnology is a specialist in immunotechnology and combines expertise in three key areas - sample bio-analysis, assay development, and IVD test production - into one complete service.
The company claims it is committed to boosting clinical trials and to providing new theranostic solutions.
It is currently focusing on protein biomarkers of clinical interest and their applications for in vitro diagnostics and is keen to expand its operations across northern Europe, including the UK.
Indicia Biotechnology utilises the Singulex Erenna immunoassay system, which uses a robust digital molecule-counting module to count photons.
This technology allows for the possibility of measuring biological molecules on the femtogram scale.
This offers a very high sensitivity level.
Indicia Biotechnology constructs tailor-made bioanalytical testing services and develops new tests.
The company's list of services includes 50 parameters across five therapeutic fields (inflammation, oncology, metabolism, neurology and cardiology).
Its services are also based on techniques such as Elisa and Luminex's Xmap, as well as immunochromatography and monoclonal antibodies.
Indicia Biotechnology is active in a range of areas, such as immunogenicity; immunomonitoring; efficacy and safety surveys; the setting-up of quality control methods; and point-of-care diagnostics.
